Clinical Trial Detail

NCT ID NCT02675829
Title Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

urinary bladder cancer

lung cancer

urinary system cancer

Advanced Solid Tumor

Therapies

Ado-trastuzumab emtansine

Age Groups: adult senior

Additional content available in CKB BOOST